ritlecitinib alopecia
Selected indexed studies
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. (Lancet, 2023) [PMID:37062298]
- European expert consensus statement on the systemic treatment of alopecia areata. (J Eur Acad Dermatol Venereol, 2024) [PMID:38169088]
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. (J Eur Acad Dermatol Venereol, 2025) [PMID:39445776]
_Worker-drafted node — pending editorial review._
Connections
ritlecitinib alopecia is a side effect of
Sources
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. (2025) pubmed
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. (2023) pubmed
- Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. (2025) pubmed
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. (2024) pubmed
- European expert consensus statement on the systemic treatment of alopecia areata. (2024) pubmed
- Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians. (2025) pubmed
- Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. (2023) pubmed
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. (2025) pubmed
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. (2024) pubmed
- PMID:40209012 (2024) pubmed